Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Liquidia Corporation filings document a Delaware biopharmaceutical issuer reporting on YUTREPIA commercialization, treprostinil products and pulmonary hypertension programs. Form 8-K reports furnish quarterly and annual financial results, Regulation FD disclosures, corporate updates and investor presentation materials tied to PAH, PH-ILD, PRINT® Technology and the company’s product portfolio.
The filing record also covers governance and capital-market disclosure subjects, including definitive proxy materials, officer appointments and material definitive agreements. Recent agreement disclosures include the Liquidia Technologies licensing arrangement with Vectura for L606 and a nebulizer device in hypertension and interstitial lung disease treatment fields.
Issuer LQDA filed a Rule 144 notice reporting an intended sale of 200,000 shares of common stock. The filing lists multiple recent sales by Canaan VIII LP in the past three months, with dated entries and per‑trade share counts and dollar amounts, including a 06/10/2026 sale of 94,365 shares for 6,039,000.
Liquidia Corp Chief Development Officer Sanjeev Khindri reported an open-market sale of 4,134 shares of common stock on June 8, 2026 at a price of $65.46 per share. After this transaction, he directly holds 67,132 common shares.
According to the footnotes, the sale was effected under a Rule 10b5-1 trading plan adopted on March 9, 2026 and was made to cover taxes tied to the settlement of previously granted restricted stock units. The filing also notes additional equity incentives, including 27,744 unvested RSUs from a February 10, 2025 grant and 34,274 RSUs granted on January 16, 2026 that had not vested as of this Form 4.
Liquidia Corp director-affiliated entity reports open-market share sales. A fund associated with director Stephen M. Bloch sold a total of 220,835 shares of Liquidia common stock in open-market transactions on June 8 and June 9, at weighted average prices around $64–$66 per share.
The securities are held directly by Canaan VIII L.P., whose investment and voting decisions are made collectively by the managers of Canaan Partners VIII LLC. Bloch disclaims beneficial ownership of these securities except to any pecuniary interest through his interests in Canaan Partners VIII LLC and did not participate in the investment decision due to a communications-screen policy. Separately, the filing shows Bloch directly holding 65,712 Liquidia shares.
Liquidia Corp director Paul B. Manning reported open-market sales of 200,000 shares of common stock on June 4, 2026. The shares were sold indirectly through entities he controls or co-manages at weighted average prices in the low-to-mid $60s per share, with price ranges between about $62.21 and $64.61 as disclosed in multiple footnotes.
After these transactions, the filing shows Manning with ongoing indirect holdings in investment vehicles and joint accounts, as well as direct ownership, including 3,131,794 shares held by the Paul B. Manning Revocable Trust where he has sole voting and investment power.
Liquidia Corporation filed a report to share that it will be added to the S&P SmallCap 600® Index, effective before the market opens on June 22, 2026. The company highlights this as a milestone reflecting its market capitalization, liquidity, publicly traded float and profitability profile.
Liquidia develops therapies for challenging respiratory and vascular diseases using its PRINT® technology, including YUTREPIA® (treprostinil) inhalation powder, the investigational L606 formulation and a marketed generic Treprostinil Injection. The company notes that forward-looking statements about visibility, strategy and long-term value are subject to risks described in its SEC filings.
Liquidia Corp director-related entity sells shares while retaining a large position. An investment entity associated with director Stephen M. Bloch, Canaan VIII L.P., sold a total of 84,800 shares of Liquidia common stock in open-market transactions on June 4–5, 2026 at weighted average prices around $64–$66 per share. The filing states these securities are held by the Canaan entities, that Dr. Bloch disclaims beneficial ownership beyond any pecuniary interest, and that he did not participate in the investment decision due to a communications-screen policy. After these sales, the filing reports 1,785,242 shares held indirectly through Canaan entities and 65,712 shares held directly.
Canaan VIII LP reported a proposed sale of 200,000 shares of common stock of LQDA via a Form 144 notice. The filing lists multiple sales by Canaan VIII LP during the prior three months, including 115,200 shares on 06/08/2026 and 318,893 shares on 05/11/2026. Broker/intermediary information shows UBS Financial Services Inc as the broker-dealer handling the transaction.
LQDA submitted a notice under Form 144 reporting the proposed sale of 200,000 shares of Common Stock through Fidelity Brokerage Services LLC with a transaction date of 06/04/2026. The filing lists prior issuances of 100,000 shares in a Registered Direct Offering on 04/13/2022 and 100,000 shares in a Private Investment in Public Equity on 12/27/2019.
The filing shows execution via Nasdaq and records holder and quantity details; no proceeds, price, or sales completed in the past three months are disclosed in the excerpt.
LQDA Rule 144 notice reports proposed resale of common stock. The filing lists 200,000 shares associated with UBS Financial Services and shows shares outstanding 88,114,400 as of 06/04/2026. It also records a prior sale of 318,893 shares by Canaan VIII LP on 05/11/2026.
Liquidia Corp’s Chief Human Resource Officer Sarah Krepp reported a small open-market sale of common stock. On June 1, 2026, she sold 276 shares at $60.87 per share in a transaction classified as an open-market sale.
According to the footnotes, the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023 and was specifically to cover taxes tied to the settlement of previously granted RSUs. After this transaction, Krepp holds 146,743 shares directly, including substantial unvested RSUs and shares acquired under the company’s employee stock purchase plan.